Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics Inc.

In a report released today, Sadia Rahman from Wells Fargo maintained a Buy rating on Dianthus Therapeutics, with a price target of $135.00. In addi...

Dianthus Therapeutics (DNTH) Receives a Buy from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH), Equillium (EQ) and Kod...

Market Cap	$1.53B	P/E Ratio	N/A
52W High	$88.49	52W Low	$13.37
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	50.2%	52W Position	96.9%
Overall Score	61	Value Score	60
Quality Score	34	Technical Score	91

EPS Current Est	$-4.46	EPS Next Est	$-5.03
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNTH	$86.20	0.00%	349.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNTH	$86.20	0%	349.20K
3
4
5
6

DNTH

DNTH

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Dianthus Therapeutics Inc. Data in Excel

Get Dianthus Therapeutics Inc. Data in Excel